Neuraxpharm Group has announced the launch of its first products in the United Kingdom, as well as the appointment of the company’s new general manager Craig Bowen, who will run Neuraxpharm UK, based in Reading.
The specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders plans to launch differentiated and specialty generics in the UK, one of the biggest markets in Europe. The UK’s CNS pharmaceutical market represents 11% of the total CNS market in Europe which is valued at GBP 2.9 billion (EUR 3.2 billion).
Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm said: “Establishing a strong presence in the UK will enable us to build on our position as a CNS specialist in Europe offering consumer healthcare products, standard generics and added value medicines. We are very pleased to welcome Craig to the Neuraxpharm team. His proven track record of launching new pharmaceutical products will be of great advantage in bringing differentiated products to local patients and healthcare professionals in the UK, one of the top five markets in Europe.”
The company has a complete spectrum of therapeutic options in epilepsy, Parkinson's, psychosis / schizophrenia, depression and Alzheimer's as well as a growing portfolio in other CNS indications, which includes more than 130 CNS molecules in the categories of analgesics, antidementia agents, antidepressants, antiepileptics, antiparkinson agents, antipsychotics, anxiolytics/hypnotics and other CNS categories.